Sibeprenlimab — Drug Intelligence | 3 EU Trials

Filter these 3 trials by condition, phase, country and more.

3 Registered trials

1 Recruiting

2 Completed trials

2 Sponsors

14 Countries

Phase III

Phase II/III

Phase II

Phase III: 1 Phase II/III: 1 Phase II: 1

Oversight events:

1 corrective measure across 1 trial

Indications tested

3 total

Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN). Recruiting

2023-507233-19-00 Phase II/III 12 countries Otsuka Pharmaceutical Development & Commercialization Inc.
Trial of Sibeprenlimab in the Treatment of Sjögren’s Disease Ended

2024-516295-14-00 Phase II 6 countries Otsuka Pharmaceutical Development & Commercialization Inc.
VISIONARY Trial: Phase 3 Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) Ended

2022-500079-30-00 Phase III 12 countries Otsuka Pharmaceutical Development And Commercialization Inc.

Showing 1–3 of 3 trials